The role of radiation in the perioperative treatment of esophagogastric cancer.
Cancers of the esophagus, stomach, and the esophagogastric junction (EGJ) remain a global health problem. There has been a dramatic increase in the incidence of adenocarcinoma of the distal esophagus and EGJ in the past two decades with little change in the poor prognosis associated with these cancers. Previously surgery alone was the mainstay of therapeutic intervention, but high rates of local and systemic failure have prompted investigation into neoadjuvant and adjuvant therapy. Treatment paradigms differ across continents, but the unifying theme that has emerged in the past decade implies that surgery alone can no longer be considered the standard of care. The multi-disciplinary management of patients with locally advanced esophagogastric carcinomas using trimodality therapy with radiotherapy, chemotherapy, and surgery confers the greatest opportunity for margin negative resection, improved loco-regional control and cure, and should be the accepted treatment paradigm. The traditional backbone of platinum plus fluorouracil concurrent with radiotherapy may be supplanted by more modern, easier-to-administer regimens incorporating taxanes and irinotecan. The current generation of clinical trials in this heterogeneous group of diseases is examining targeted therapy, newer methods of radiotherapy, and predictors of response to therapy aiming to tailor management to an individual patient.
Department of Radiation Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Kilian S
KS
May
Gary Y
GY
Yang
Nikhil I
NI
Khushalani
D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000532:radiotherapy* / Q000601:surgery*; D004943:Esophagogastric Junction / Q000528:radiation effects / Q000601:surgery; D006801:Humans; D059035:Perioperative Period; D011379:Prognosis; D011879:Radiotherapy Dosage; D013274:Stomach Neoplasms / Q000532:radiotherapy* / Q000601:surgery*
N Engl J Med. 1992 Jun 11;326(24):1593-8
1584260
J Clin Oncol. 2007 Aug 20;25(24):3719-25
17704421
J Surg Oncol. 2005 Jun 1;90(3):139-46; discussion 146
15895452
J Clin Oncol. 2005 Jul 1;23(19):4330-7
15781882
J Clin Oncol. 2009 Oct 20;27(30):5062-7
19770374
Lancet Oncol. 2005 Sep;6(9):659-68
16129366
Cancer Treat Rev. 2007 Dec;33(8):729-40
17935888
Jpn J Surg. 1989 May;19(3):290-5
2779027
Radiother Oncol. 2009 Aug;92(2):164-75
19375186
N Engl J Med. 1996 Aug 15;335(7):462-7
8672151
Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):283-93
11872272
World J Surg. 1996 May;20(4):507-10 discussion 511
8662143
J Clin Oncol. 2002 Mar 1;20(5):1167-74
11870157
N Engl J Med. 1998 Dec 31;339(27):1979-84
9869669
Gastrointest Cancer Res. 2008 Jul;2(4 Suppl):S2-5
19343142
Cancer. 2005 Dec 1;104(11):2365-72
16245310
Ann Surg. 2000 Sep;232(3):353-61
10973385
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
15761078
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
20610543
J Clin Oncol. 1997 Jan;15(1):277-84
8996153
J Clin Oncol. 2008 Mar 1;26(7):1086-92
18309943
N Engl J Med. 2001 Sep 6;345(10):725-30
11547741
Ann Surg Oncol. 2008 Feb;15(2):500-7
18026800
J Clin Oncol. 2002 Jun 15;20(12):2844-50
12065561
J Clin Oncol. 2006 Sep 10;24(26):4347-55
16963732
Cancer. 1998 Nov 15;83(10):2049-53
9827707
Cancer Invest. 2009 Feb;27(2):193-200
19235592
JAMA. 1991 Mar 13;265(10):1287-9
1995976
Br J Surg. 1998 Nov;85(11):1457-9
9823902
JAMA. 1999 May 5;281(17):1623-7
10235156
N Engl J Med. 2006 Jul 6;355(1):11-20
16822992
J Clin Oncol. 2009 Feb 20;27(6):851-6
19139439
Lancet Oncol. 2007 Mar;8(3):226-34
17329193
Lancet. 2002 May 18;359(9319):1727-33
12049861
J Clin Oncol. 2001 Jan 15;19(2):305-13
11208820